Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL IN PLASTIC CONTAINER versus PENICILLIN G PROCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL IN PLASTIC CONTAINER versus PENICILLIN G PROCAINE.
BACTOCILL IN PLASTIC CONTAINER vs PENICILLIN G PROCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity essential for peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
1-2 g intravenously every 4 hours.
1.2 million to 2.4 million units intramuscularly once daily for most infections (e.g., uncomplicated pneumonia); for neurosyphilis, 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10-14 days. Administer deep IM injection, not IV.
None Documented
None Documented
30-60 minutes (mean 40 min) in adults with normal renal function; prolonged to 7-10 hours in anuria. Clinical context: dosing interval adjustment required in renal impairment.
Terminal elimination half-life is approximately 0.5-1 hour in patients with normal renal function. Clinically, the prolonged absorption from the intramuscular depot results in sustained serum concentrations, with effective levels lasting 12-24 hours.
Primarily renal (60-70% unchanged by tubular secretion and glomerular filtration); biliary/fecal excretion accounts for <30%.
Primarily renal excretion via tubular secretion and glomerular filtration. Approximately 60-90% of a dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination is minor (<10%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic